Rituximab in the treatment of thyroid eye disease: Science fiction?

Mario Salvi, Guia Vannucchi, Irene Campi, Paolo Beck-Peccoz

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Lately, monoclonal antibodies directed to molecules of the immune system have become available. Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody which blocks the activation and differentiation of B cells. The rationale for use in Graves' disease (GD) and orbitopathy is the potential effect on B-cell mediated immunity. Transient B cell depletion may modify the active inflammatory phase of thyroid eye disease (TED). We have studied nine patients with GD, of whom seven had active TED and two only lid signs. All but one patients showed both CD20 cells and CD19 cells depletion with the first RTX infusion, while one had persistent 3-5% CD19 cells. RTX was well tolerated and only minor side effects were reported in three patients at first infusion. Circulating antithyroglobulin, antithyroperoxidase and anti-TSH receptor antibodies did not change significantly and did not correlate to CD20 depletion. The clinical activity score value was 4.7±0.5 before therapy and 1.8±0.8 at the end of follow-up (P

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalOrbit
Volume28
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Eye Diseases
Thyroid Diseases
B-Lymphocytes
Graves Disease
Monoclonal Antibodies
Cellular Immunity
Immune System
Therapeutics
Rituximab

Keywords

  • Corticosteroids
  • Graves orbitopathy
  • Immunosuppression
  • Rituximab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Rituximab in the treatment of thyroid eye disease : Science fiction? / Salvi, Mario; Vannucchi, Guia; Campi, Irene; Beck-Peccoz, Paolo.

In: Orbit, Vol. 28, No. 4, 2009, p. 251-255.

Research output: Contribution to journalArticle

Salvi, M, Vannucchi, G, Campi, I & Beck-Peccoz, P 2009, 'Rituximab in the treatment of thyroid eye disease: Science fiction?', Orbit, vol. 28, no. 4, pp. 251-255. https://doi.org/10.3109/01676830903104611
Salvi, Mario ; Vannucchi, Guia ; Campi, Irene ; Beck-Peccoz, Paolo. / Rituximab in the treatment of thyroid eye disease : Science fiction?. In: Orbit. 2009 ; Vol. 28, No. 4. pp. 251-255.
@article{6fa5b8add7f24915a35bcdabbe676491,
title = "Rituximab in the treatment of thyroid eye disease: Science fiction?",
abstract = "Lately, monoclonal antibodies directed to molecules of the immune system have become available. Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody which blocks the activation and differentiation of B cells. The rationale for use in Graves' disease (GD) and orbitopathy is the potential effect on B-cell mediated immunity. Transient B cell depletion may modify the active inflammatory phase of thyroid eye disease (TED). We have studied nine patients with GD, of whom seven had active TED and two only lid signs. All but one patients showed both CD20 cells and CD19 cells depletion with the first RTX infusion, while one had persistent 3-5{\%} CD19 cells. RTX was well tolerated and only minor side effects were reported in three patients at first infusion. Circulating antithyroglobulin, antithyroperoxidase and anti-TSH receptor antibodies did not change significantly and did not correlate to CD20 depletion. The clinical activity score value was 4.7±0.5 before therapy and 1.8±0.8 at the end of follow-up (P",
keywords = "Corticosteroids, Graves orbitopathy, Immunosuppression, Rituximab",
author = "Mario Salvi and Guia Vannucchi and Irene Campi and Paolo Beck-Peccoz",
year = "2009",
doi = "10.3109/01676830903104611",
language = "English",
volume = "28",
pages = "251--255",
journal = "Orbit",
issn = "0167-6830",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Rituximab in the treatment of thyroid eye disease

T2 - Science fiction?

AU - Salvi, Mario

AU - Vannucchi, Guia

AU - Campi, Irene

AU - Beck-Peccoz, Paolo

PY - 2009

Y1 - 2009

N2 - Lately, monoclonal antibodies directed to molecules of the immune system have become available. Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody which blocks the activation and differentiation of B cells. The rationale for use in Graves' disease (GD) and orbitopathy is the potential effect on B-cell mediated immunity. Transient B cell depletion may modify the active inflammatory phase of thyroid eye disease (TED). We have studied nine patients with GD, of whom seven had active TED and two only lid signs. All but one patients showed both CD20 cells and CD19 cells depletion with the first RTX infusion, while one had persistent 3-5% CD19 cells. RTX was well tolerated and only minor side effects were reported in three patients at first infusion. Circulating antithyroglobulin, antithyroperoxidase and anti-TSH receptor antibodies did not change significantly and did not correlate to CD20 depletion. The clinical activity score value was 4.7±0.5 before therapy and 1.8±0.8 at the end of follow-up (P

AB - Lately, monoclonal antibodies directed to molecules of the immune system have become available. Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody which blocks the activation and differentiation of B cells. The rationale for use in Graves' disease (GD) and orbitopathy is the potential effect on B-cell mediated immunity. Transient B cell depletion may modify the active inflammatory phase of thyroid eye disease (TED). We have studied nine patients with GD, of whom seven had active TED and two only lid signs. All but one patients showed both CD20 cells and CD19 cells depletion with the first RTX infusion, while one had persistent 3-5% CD19 cells. RTX was well tolerated and only minor side effects were reported in three patients at first infusion. Circulating antithyroglobulin, antithyroperoxidase and anti-TSH receptor antibodies did not change significantly and did not correlate to CD20 depletion. The clinical activity score value was 4.7±0.5 before therapy and 1.8±0.8 at the end of follow-up (P

KW - Corticosteroids

KW - Graves orbitopathy

KW - Immunosuppression

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=70350694454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350694454&partnerID=8YFLogxK

U2 - 10.3109/01676830903104611

DO - 10.3109/01676830903104611

M3 - Article

C2 - 19839884

AN - SCOPUS:70350694454

VL - 28

SP - 251

EP - 255

JO - Orbit

JF - Orbit

SN - 0167-6830

IS - 4

ER -